- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00602355
Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression
Placebo Controlled Trial of Sertraline and Interpersonal Psycho-Therapy for Postpartum Depression
Study Overview
Status
Conditions
Detailed Description
Postpartum depression (PPD) occurs in approximately 13% of postpartum women. The impact of PPD is significant, including emotional distress for the woman as well as disturbances in infant development. Common signs of depression after childbirth may include anxiety, irritability, low energy, and lack of concern for self or infant. If left untreated, PPD may last for more than 1 year, causing strain on family life and the mother's relationship with her infant. Infants of depressed mothers are also at a higher risk for developmental delays, behavioral problems, and difficulty eating and sleeping. Despite the public health significance of PPD, relatively little research has been done to determine the most effective treatments. Specifically, there is a lack of research concerning the use of antidepressant medication for treating PPD. Interpersonal psychotherapy (IPT), which focuses on interpersonal issues related to depression, has been more thoroughly studied for the treatment for PPD, but it has not been compared to the other treatment. This study will evaluate the effectiveness of antidepressant medication alone and IPT alone in treating women with PPD.
Participation in this double-blind study will last 9 months. Participants will first undergo initial assessments, which include interviews about depressive symptoms, self-report forms about medical history, blood tests, and a pregnancy test. Participants will then be randomly assigned to one of three treatments: sertraline, placebo, or IPT. All three treatments will be administered over 13 weeks. Participants assigned to take sertraline or placebo will attend nine 30-minute sessions over the 13-week treatment period. During these sessions, participants will be administered the study medication and will be assisted with parenting issues and skills by a psychiatrist. Participants receiving IPT will attend weekly 50-minute sessions over the 13-week treatment period. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills. All participants will also complete interviews and questionnaires about their depression once a month. Following the 13 weeks of treatment, participants will undergo follow-up assessments at Months 3 and 6 post-treatment. Follow-up assessments will repeat initial interviews and questionnaires and will include a form about the infant's nature.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Women and Infants Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary DSM-IV diagnosis of major depressive disorder by clinical interview
- Score of greater than 12 on HAM-D
- Delivery of an infant within the 12 months prior to study entry
- Able to speak and read English sufficiently to complete the study procedures
- Willing to use effective birth control methods throughout the study
Exclusion Criteria:
- Woman whose infant has died prior to study entry
- Current or past diagnosis of bipolar disorder, schizophrenia or other psychotic disorder;
- Diagnosis of alcohol or drug abuse or dependence (except nicotine) or anorexia in the past year;
- Psychotic symptoms;
- Acute suicidal or homicidal risks;
- Women who have been on an antidepressant for more than 14 days prior to consent, (if less than 14 days and willing to taper off, will be eligible to continue once tapered off);
- Women on daily anxiolytic medication (i.e. benzodiazepine, buspirone) or daily psychoactive herbal preparation (St. John's Wort or Fish Oil) (if willing to discontinue these substances may be eligible once they have been tapered off);
- Medications taken PRN over the listed dose and frequency (women will still be eligible if they take: Lunesta/Eszopiclone 3 mg or less, up to 3 nights a week, Ambien/Zolpidem 5mg or less, Ambien CR 6.25 mg or less, up to 3 nights a week, Lorazepam or equivalent benzodiazepine dose: 0.5 mg up to 3 nights a week, Sonata/Zaleplon: 5 mg or less, up to 3 nights a week, Rozerem/Ramelteon: 8 mg or less, up to 3 nights a week);
- If they take antidepressants PRN for insomnia (eg: Desyrel/Trazodone, Elavil/Amitriptyline, Remeron/Mirtazapine;
- Ongoing concurrent psychotherapeutic treatment or psychotherapeutic treatment within the last month;
- Psychiatric symptoms requiring specialized psychiatric treatment;
- Significant medical disorder that would make sertraline treatment contra-indicated,
- Previous trial of IPT therapy with a certified IPT therapist or an adequate trial of sertraline (i.e. at least 8 weeks of at least 100 mg daily of sertraline).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1 (Placebo)
Participants receiving placebo pill with clinical management plus mothercrafting
|
Participants taking the placebo will follow the same titration schedule as those taking sertraline.
In addition, the participates will receive the same specific "mother-crafting" techniques as those taking sertraline.
Clinical management includes treatment as usual for those receiving medication for depression.
Mother-crafting techniques are keyed to the baby's age and development.
The mother-crafting component is aimed at providing relevant information about infant care
|
Active Comparator: 2 (Sertraline)
Participants receiving active medication sertraline with clinical management plus mothercrafting
|
Clinical management includes treatment as usual for those receiving medication for depression.
Mother-crafting techniques are keyed to the baby's age and development.
The mother-crafting component is aimed at providing relevant information about infant care
Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10.
Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment.
In addition, at each week participants will receive specific "mother-crafting" techniques keyed to the baby's age and development.
The mother-crafting component is aimed at providing relevant information to the mother about infant care.
Other Names:
|
Active Comparator: 3 (IPT)
Participants receiving interpersonal psychotherapy (IPT) alone
|
IPT will be administered in 13 individual 50-minute sessions over 13 weeks.
These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Depression Rating Scale (HAM-D)
Time Frame: Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Measure total ranges from 0 to 50, with lower scores indicating better outcomes.
|
Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression Illness Severity Based on Beck Depression Inventory (BDI)
Time Frame: Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Measure total ranges from 0 to 56, with lower scores indicating better outcomes.
|
Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Global Illness Severity Based on Clinical Global Impression (CGI) Scale
Time Frame: Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Measure total ranges from 1 to 7, with lower scores indicating better outcomes.
|
Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Social Functioning Based on Postpartum Adjustment Questionnaire (PPAQ)
Time Frame: Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Measure total ranges from 1 to 5, with lower scores indicating better outcomes.
|
Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Hamilton Anxiety Rating Scale (HARS)
Time Frame: Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Measure total ranges from 0 to 56, with lower scores indicating better outcomes.
|
Measured at baseline; post-treatment; and Months 3 and 6 of follow-up
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Caron Zlotnick, Women and Infants Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Pregnancy Complications
- Puerperal Disorders
- Depression
- Depressive Disorder
- Depression, Postpartum
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Sertraline
Other Study ID Numbers
- R01MH074919 (U.S. NIH Grant/Contract)
- DSIR 83-ATP (NCT00719979)
- R01MH074636 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Postpartum
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Women's Health Research Institute...CompletedPostpartum Depression | Perinatal Disorder | Postpartum Disorder | Perinatal Depression | Postpartum Anxiety | Postnatal DepressionCanada
-
University of CoimbraEnrolling by invitationPostPartum DepressionPortugal
-
University of MinnesotaNational Institute of Mental Health (NIMH)Completed
-
Sage TherapeuticsCompletedSevere Postpartum DepressionUnited States
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); Michael Garron HospitalCompletedPostpartum Depression | Postpartum Anxiety | Postpartum Blues | Postpartum Mood DisorderCanada
-
Gazi UniversityCompletedPostpartum Depression | Postpartum AdaptationTurkey
-
British Columbia Children's HospitalActive, not recruiting
-
University of RochesterMae Stone Goode FoundationCompletedPostpartum Depression | Postpartum AnxietyUnited States
-
Hacettepe UniversityCompletedQuality of Life | Postpartum Depression | Nursing Caries | Nurse's Role | Postpartum Disorder | Postpartum AnxietyTurkey
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States